Raghvendra Srivastava, PhD

Assistant Professor
Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Raghvendra M. Srivastava, Ph.D., is an Assistant professor at Cleveland Clinic Lerner College of Medicine, and director of the Discovery lab at Center for Immunotherapy and Precision Immuno-Oncology (CITI). Dr. Srivastava has been a Research Instructor (faculty) at the University of Pittsburgh Hillman Cancer Center. and Senior Scientist in Immunogenomics laboratory under Dr. Timothy A. Chan at MSKCC and ran Immunological operations and several collaborative cancer immunology projects.  His doctorate in cancer immunology and more than 12 years of experience in the field of cancer antigens and diverse Immuno-Oncology puts him in a unique position to run collaborative laboratory and cancer immunology projects. As a basic/translational cancer immunology laboratory, he is uniquely positioned to investigate mechanisms of anti-tumor immunity in the tumor microenvironment, as well as, discover tumor cell escape mechanisms in a wide variety of cancer types.  In these capacities, Dr. Srivastava facilitates and enhances the development of new targets, decipher novel genomic mechanisms of actions of immunomodulatory drugs, and develops novel therapeutic agents through collaborative, trans-disciplinary preclinical research and clinical application at Cleveland Clinic.

Dr. Srivastava focuses on using high-throughput immunological methods and several next-generation single-cell sequencing technology platforms to unravel genomic determinants of cancer immunotherapy. He has published several papers focused on the development of cancer antigens, neoantigens, and establishing precision-based cancer immunotherapy programs for patients. His primary research area includes the understanding of the mechanism of action of FDA-approved immune checkpoint inhibitors on T cell responses and defining the role of genetic mutations in oncogenesis, neoantigens generation, and cancer recognition and elimination. These strategies help in patient selection criteria and enhance the efficacy of FDA-approved immune checkpoint inhibitors.

Awards and Honors

First prize on ‘National Science Day’ poster prize competition
2000
DBT

Professional Memberships

Member, Society of immunotherapy of Cancer (SITC): 2012, 2014, 2015, 2020, 2021
Member, American Association of Immunologist: 2014
Member, International Society of infectious diseases: 2017- 2018

Education

PhD
Cancer Immunology
CCMB, Hyderabad
2007
MS
Bio-Technology
Institute of Science-BHU, Varanasi
2000
BS
Chemistry (HONS)
Institute of Science-BHU, Varanasi
1998

Residencies, Internships and Fellowships

Senior Research Fellowship
CSIR Scholarship support
2004
Junior Research Fellowship
CSIR Scholarship support
2002